Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this research project is to study small airways physiological function in patients with chronic obstructive lung disease or COVID-19 and explore the relationship with in-vivo microanatomical small airway structure as measured by OCT. Correlating endobronchial assessment with multiple breath nitrogen washout and impulse oscillometry will allow the characterisation of the relationship between small airway structural findings and these validated investigations. A small volume lung wash, endobronchial brushings and the collection of a limited number of endobronchial cryobiopsy samples will be performed to better understand the endobronchial environment of the small airways through inflammatory studies. Following the completion of any such work, residual samples will be stored in a "bio-bank" to enable the completion of future work. Understanding the relationship with symptom-based quality of life scoring questionnaires and a functional assessment of exercise capacity will help elucidate the clinical impact of in-vivo small airways findings.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Chronic Airflow obstruction / COVID-19 | Patients with either chronic airflow obstruction of COVID-19 |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Respiratory resistance at 5Hz - 20Hz (R5-R20) (kPa/l/s) related to airtrapping as determined by quantitative CT (Expiratory phase low attenuation area <856 HU (%LAA <856 HU) | Impulse Oscillometry | Baseline, pre-procedure |
| Measure | Description | Time Frame |
|---|---|---|
| Respiratory reactance at 5Hz: X5 (kPa/l/s) | Impulse Oscillometry | Baseline, pre-procedure |
| Reactance area: Ax (kPa/l/s) | Impulse Oscillometry |
| Measure | Description | Time Frame |
|---|---|---|
| Exploratory: Inflammatory and pathological studies of airways brush, wash and cryobiopsy samples | Laboratory based scientific studies | Baseline, during the procedure |
Inclusion Criteria:
Age 16 or over
Scheduled for bronchoscopy as part of clinical care or research protocol
No bleeding diathesis or therapeutic anticoagulation
COPD:
Asthma:
Exclusion Criteria:
Unable to provide informed consent
Exacerbation of obstructive airways disease or respiratory infection requiring systemic antibiotics or corticosteroids in the 6 weeks prior to enrolment unless suffering from COVID-19 infection and bronchoscopy is required for clinical reasons
Contra-indications to performing lung function testing
Contra-indications to passing oesophageal balloons
Not provided
Not provided
Not provided
Subjects over the age of 16 with either chronic airflow obstruction or COVID-19
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Christopher M Orton, MBBS | Contact | 02073518029 | 8029 | c.orton@rbht.nhs.uk |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Royal Brompton | Recruiting | London | United Kingdom |
Not provided
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| D000086382 | COVID-19 |
| D001249 | Asthma |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline, pre-procedure |
| Functional residual capacity by MBNW: FRCgas (L) | Multiple Breath Nitrogen Washout | Baseline, pre-procedure |
| Lung clearance index: LCI | Multiple Breath Nitrogen Washout | Baseline, pre-procedure |
| Ventilation heterogeneity conducting airways: Scond (L/s) | Multiple Breath Nitrogen Washout | Baseline, pre-procedure |
| Ventilation heterogeneity acinar airways: Sacin (L/s) | Multiple Breath Nitrogen Washout | Baseline, pre-procedure |
| Forced expiratory volume in 1 second: FEV1 (L) | Spirometry | Baseline, pre-procedure |
| Forced vital capacity: FVC (L) | Spirometry | Baseline, pre-procedure |
| Total lung capacity: TLC (L) | Plethysmography | Baseline, pre-procedure |
| Residual volume: RV (L) | Plethysmography | Baseline, pre-procedure |
| Functional residual capacity by plethysmography: FRCpleth (L) | plethysmography | Baseline, pre-procedure |
| Airway mean luminal diameter (Dmean) | Optical Coherence Tomography | Baseline, during the procedure |
| Airway inner lumen area (Ai) | Optical Coherence Tomography | Baseline, during the procedure |
| Airway wall area (Aw), airway wall percentage (Aw%) as determined by [Aw/(Ai + Aw) × 100%] | Optical Coherence Tomography | Baseline, during the procedure |
| Air trapping - expiratory phase low attenuation area <856 HU (%LAA <856 HU) | Quantitative CT | Baseline, pre-procedure |
| Modified MRC dyspnoea score | Patient reported outcome measure | Baseline, pre-procedure |
| St George's Respiratory Questionnaire Score | Patient reported outcome measure | Baseline, pre-procedure |
| Asthma-related Quality of Life Questionnaire (AQLQ) (if asthmatic) | Patient reported outcome measure | Baseline, pre-procedure |
| Asthma Control Questionnaire (ACQ) (if asthmatic) | Patient reported outcome measure | Baseline, pre-procedure |
| 6-minute walk distance (m) | 6-minute walk distance (m) | Baseline, pre-procedure |
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D001982 | Bronchial Diseases |
| D012130 | Respiratory Hypersensitivity |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |